Torpy, David J, Bachmann, A W, Gartside, M et al. · Endocrine research · 2004 · DOI
This study investigated whether a specific genetic variation in a gene called CBG (corticosteroid-binding globulin) might increase the risk of developing ME/CFS. The researchers compared 248 ME/CFS patients with 248 healthy controls and found a trend suggesting that people with two copies of a particular genetic variant (called serine224) were more common among ME/CFS patients. This variant was associated with higher CBG levels in the blood but lower cortisol levels, which could affect how the body manages stress and inflammation.
Understanding genetic factors in ME/CFS susceptibility could help identify at-risk individuals and reveal biological mechanisms underlying the disease. The connection to cortisol regulation and immune function is particularly relevant since HPA axis dysfunction is a recognized feature of ME/CFS. This work provides a foundation for investigating whether CBG function is a therapeutic target.
This study does not prove that the CBG polymorphism causes ME/CFS—the trend was not statistically significant (P = 0.07) and the findings are correlational. It does not establish whether the genetic variation is necessary or sufficient for disease development, nor does it clarify the mechanism by which it might contribute to ME/CFS pathology. The cross-sectional cortisol measurements (single 8–10 a.m. samples) limit conclusions about HPA axis dynamics.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →